BGM Group vs Cumberland Pharmaceuticals
Cumberland Pharmaceuticals is the larger business, with $44.5m of revenue in fiscal 2025 against $37.9m for BGM Group (1.2 times as much). BGM Group grew faster (51.1% against 17.6%). Cumberland Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -6.4% against -52.6%.
| Latest fiscal year | BGM GroupBGM, 2025 | Cumberland PharmaceuticalsCPIX, 2025 |
|---|---|---|
| Revenue | $37.9m | $44.5m |
| Revenue growth | 51.1% | 17.6% |
| Net income | −$19.9m | −$2.8m |
| Operating margin | — | -6.3% |
| Net margin | -52.6% | -6.4% |
| Return on equity | -9.2% | -11.9% |
| Free cash flow | −$3.9m | $4.8m |
| Cash | $9.8m | $11.4m |
| Total debt | $0 | $5.2m |
| Debt to equity | — | 21.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $263,478 |
| Employees | — | 93 |
| Market value | $1.91bn | $64.4m |
| Price vs our value range | — | Above our value range |
| Moat score | — | 57 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |